中基健康(000972) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was approximately ¥174.45 million, representing a 659.61% increase compared to ¥22.97 million in 2020[19]. - The net profit attributable to shareholders for 2021 was a loss of approximately ¥100.52 million, an improvement from a loss of ¥265.89 million in 2020[19]. - The net cash flow from operating activities for 2021 was a negative ¥188.67 million, compared to a negative ¥9.89 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥682.34 million, an increase of 17.14% from ¥582.51 million at the end of 2020[19]. - The net assets attributable to shareholders decreased by 57.10% to approximately ¥75.52 million at the end of 2021 from ¥176.04 million at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.13, an improvement from -¥0.34 in 2020[19]. - The weighted average return on net assets for 2021 was -79.92%, a decrease of 6.13 percentage points from -86.05% in 2020[19]. - The company reported a net profit of -100,580,101.65 CNY for the year 2021, with a net profit attributable to shareholders of -100,520,187.08 CNY[175]. - The net loss for 2021 was CNY 100,580,101.65, compared to a net loss of CNY 266,724,598.87 in 2020, showing an improvement of approximately 62.3%[200]. Revenue and Sales - The company achieved total operating revenue of CNY 174.45 million in 2021, a significant increase from CNY 22.97 million in 2020[20]. - The total revenue for 2021 reached ¥174,451,612.86, representing a significant increase of 659.61% compared to ¥22,966,067.61 in 2020[36]. - The manufacturing sector contributed ¥165,753,883.70, accounting for 95.01% of total revenue, while rental services generated ¥7,987,472.83, a decrease of 65.09% year-over-year[36]. - The major product, bulk tomato sauce, generated revenue of ¥158,933,143.77, which is 91.10% of total revenue[36]. - Total sales amount from the top five customers reached ¥173,488,896.02, accounting for 99.44% of the annual sales[47]. Production and Operations - The company produced over 58,000 tons of bulk tomato sauce during the production period from August 8 to September 30, 2021, equivalent to 72,000 tons of standard sauce[31]. - The company produced over 58,282.83 tons of bulk tomato sauce in 2021, with a sales volume of 30,058.06 tons[40]. - The company has resumed production of high-value tomato lycopene health products to optimize its product structure[34]. - The company operates under a "leading enterprise + base + farmers" model to ensure stable raw material procurement[34]. - The company has fully restored its tomato industry production, optimizing the product structure and resuming the production of high-value tomato lycopene health products and small-packaged tomato sauce[65]. Cash Flow and Assets - The company reported a net cash flow from operating activities of CNY 72.15 million in the fourth quarter, following a negative cash flow in the previous quarters[24]. - Operating cash inflow totaled ¥170,591,574.35, a significant increase of 509.16% year-on-year[51]. - Operating cash outflow reached ¥359,266,256.30, an increase of 848.10% compared to the previous year[51]. - The company's inventory increased to ¥160,812,447.35, representing 23.57% of total assets[55]. - Fixed assets decreased to ¥315,290,506.46, accounting for 46.21% of total assets, down 14.63%[55]. Future Plans and Strategies - The company plans to apply for the removal of the delisting risk warning after the 2021 annual report disclosure, but the approval remains uncertain[5]. - The company plans to produce 80,000 tons of large-pack tomato sauce and 200,000 bottles of lycopene in the upcoming year[64]. - The company aims to achieve profitability in 2022 after a period of losses[64]. - The company is focusing on integrating and optimizing resources to reduce operational burdens through leasing arrangements[30]. - The company plans to enhance its market-oriented operational mechanism and improve cost management to boost the profitability of its tomato industry[29]. Governance and Management - The total remuneration for directors, supervisors, and senior management was CNY 1.7465 million (including tax) for the year ended December 31, 2021[90]. - The company has established a complete independent governance structure, ensuring separation from its controlling shareholder in business, personnel, assets, organization, and finance[72]. - The company is focused on maintaining transparency in its remuneration practices and ensuring compliance with relevant regulations[90]. - The company held multiple board meetings during the reporting period, including the third and fourth meetings of the eighth board and several temporary meetings, with key resolutions passed regarding the 2020 annual report and financial statements[93]. Legal and Compliance Issues - The company reported a negative net profit for the year, leading to a "delisting risk warning" from the Shenzhen Stock Exchange due to revenues falling below 100 million yuan[124]. - The company has been ordered to pay a total of RMB 124,628,370.62, which includes principal, fees, and other costs related to a legal dispute[130]. - The company has frozen assets including RMB 123,970,926.36 in deposits and dividends from its subsidiary, Xinjiang Zhongji Red Tomato Industry Co., Ltd., for a period of three years[130]. - The company has engaged a professional institution for asset evaluation related to debt compensation[133]. Social Responsibility and Environmental Impact - The company is recognized as a key agricultural industrialization enterprise and has contributed to local economic development and poverty alleviation efforts in the Xinjiang region[115]. - The company has implemented measures to reduce carbon emissions, focusing on energy conservation and enhancing wastewater treatment capabilities[113]. - The company is committed to fulfilling its social responsibilities and has established a system to regularly evaluate its social responsibility practices[114].